Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 981, doi. 10.1007/s40273-020-00929-z
- By:
- Publication type:
- Article
Works matching IS 11707690 AND DT 2020 AND VI 38 AND IP 9
Results: 10
1
2
Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 971, doi. 10.1007/s40273-020-00923-5
- By:
- Publication type:
- Article
3
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 953, doi. 10.1007/s40273-020-00922-6
- By:
- Publication type:
- Article
4
Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 927, doi. 10.1007/s40273-020-00933-3
- By:
- Publication type:
- Article
5
Financing Drug Innovation in the US: Current Framework and Emerging Challenges.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 905, doi. 10.1007/s40273-020-00926-2
- By:
- Publication type:
- Article
6
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
7
Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 995, doi. 10.1007/s40273-020-00930-6
- By:
- Publication type:
- Article
8
Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 913, doi. 10.1007/s40273-020-00921-7
- By:
- Publication type:
- Article
9
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 941, doi. 10.1007/s40273-020-00919-1
- By:
- Publication type:
- Article
10
Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 901, doi. 10.1007/s40273-020-00918-2
- By:
- Publication type:
- Article